Is metformin a possible treatment for diabetic neuropathy?

Juechun Wei | Yanling Wei | Meiyan Huang | Peng Wang | Shushan Jia

Abstract

Metformin is a hypoglycemic drug widely used in the treatment of type 2 diabetes. It has been proven to have analgesic and neuroprotective effects. Metformin can reverse pain in rodents, such as diabetic neuropathic pain, neuropathic pain caused by chemotherapy drugs, inflammatory pain and pain caused by surgical incision. In clinical use, however, metformin is associated with reduced plasma vitamin B12 levels, which can further neuropathy. In rodent diabetes models, metformin plays a neuroprotective and analgesic role by activating adenosine monophosphate-activated protein kinase, clearing methylglyoxal, reducing insulin resistance, and neuroinflammation. This paper also summarized the neurological adverse reactions of metformin in diabetic patients. In addition, whether metformin has sexual dimorphism needs further study.

KEYWORDS

adenosine monophosphate-activated protein kinase (AMPK), diabetic neuropathy, metformin, pain, vitamin B12

Highlights

• Metformin has been shown to alleviate diabetic peripheral neuropathy.
• The neuroprotective and analgesic effects of metformin are related to the activation of AMPK, the clearance of MGO, and the reduction of insulin resistance and neuroinflammation.
• AMPK activation is critical for the analgesic effect of metformin.
• AMPK activation can attenuate inflammatory response and oxidative stress, regulate autophagy and regulate ion channels.

1 | INTRODUCTION

Diabetic peripheral neuropathy (DPN) is a common complication of diabetes. DPN is mainly characterized by sensory neuropathy but can also be accompanied by autonomic neuropathy and impaired motor function. About 30% DPN patients have pain symptoms, including tingling, burning, spontaneous pain, allodynia and hyperalgesia. However, the treatment of painful diabetic peripheral neuropathy (PDPN) has been unsatisfactory, and less than 30% PDPN patients can obtain satisfactory analgesic through therapy. Metformin is an antihyperglycemic drug widely used in...
patients with type 2 diabetes mellitus (T2DM) and has been reported to have analgesic potential. Studies have shown that metformin can relieve neuropathic pain caused by diabetes, chemotherapy drugs, low back pain, osteoarthritis, postoperative pain and inflammatory pain through activating adenosine 5′-monophosphate-activated protein kinase (AMPK). Metformin also has the ability to remove methylglyoxal (MGO), a metabolite associated with PDPN. However, there is an interesting phenomenon in the clinical application of metformin—it may reduce serum vitamin B12 level, which may aggravate nerve injury.

Here, we reviewed the basic and clinical studies and summarized research status and mechanism of metformin in treating DPN. Data strongly suggested that metformin may be a promising agent in alleviating DPN. However, more clinical studies are needed to evaluate its efficacy and safety.

## EFFECTS AND MECHANISMS OF METFORMIN ON PDPN

Metformin acts through multiple pathways, including inhibiting mitochondrial respiration and gluconeogenesis, activating AMPK, increasing insulin sensitivity, antagonizing the effects of glucagon, and increasing fatty acid oxidation. It was previously thought that hyperglycemia is the main cause of PDPN, but this view has recently been challenged. In one study, feeding a 15% fructose solution to rats for 16 weeks induced generalized tactile pain and hyperalgesia without significant elevation of blood glucose levels, suggesting that the effect of fructose on pain may be due to insulin resistance rather than hyperglycemia. Allodynia and hyperalgesia in fructose-treated rats can be reversed by metformin, suggesting that its antihyperalgesia effect was not entirely dependent on hypoglycemic effect. Metformin also reversed the reduction of mechanical withdrawal threshold without changing in plasma glucose and insulin in high-fat diet/streptozotocin rats. The mechanism of metformin alleviating DPN is shown in the Figure 1 and studies involved are shown in Table 1.

### 2.1 Activation of AMPK pathway

AMPK is a ubiquitous energy-sensitive kinase consisting of two regulatory subunits (β and γ) and one catalytic subunit (α). When AMP/ATP ratio increases, AMP binding to γ-subunit and the phosphorylation at Thr172 in the α-subunit by Ca2+/calmodulin-dependent protein kinase or liver kinase B1 (LKB1) leads to indirect activation. AMPK also can be activated directly by phosphorylation of α-subunit by certain drugs such as O304. Metformin activates AMPK mainly by inhibiting mitochondrial respiratory chain complex 1 and ATP production and also acts in a LKB1-dependent fashion. Impairment of AMPK is associated with a number of pathological conditions, including obesity, exercise or metabolic syndrome, and inflammation. Recently, studies have shown that the downregulated AMPK is closely related to pain symptoms and metformin can relieve pain by activating AMPK.

---

**FIGURE 1** The mechanism of metformin alleviating DPN. Metformin can reduce inflammatory response and oxidative stress, regulate autophagy response and the activation or expression of NaV1.7 and TRPA1 channels to play analgesic and anti-hyperalgesia roles by activating AMPK. Metformin’s analgesia is also partially explained by the reduction in methylglyoxal and insulin resistance.
2.1.1 Inhibit inflammatory response and oxidative stress

Metformin activates AMPK to inhibit cytokines and reduce systemic inflammation. Peripheral nerve inflammation is one of the mechanisms of DPN. Metformin increased the expression of phosphorylated AMPK (P-AMPK, the activated state of AMPK) in dorsal root ganglia (DRG) cells, which decreased in diabetes. Compared with controls (saline), metformin reduced the serum levels of markers for inflammatory response such as C-reactive protein, interleukin-6, and tumor necrosis factor-α. Metformin increased motor nerve conduction velocity, an indicator of diabetic neuropathy, in STZ-induced diabetic mice. These results suggested metformin may play a neuroprotective role by activating AMPK to reduce inflammation.

| Study           | Mechanisms of metformin | Models                  | Doses, time, and administration route of metformin | Effects of metformin                                                                 |
|-----------------|--------------------------|-------------------------|---------------------------------------------------|-------------------------------------------------------------------------------------|
| Hasanvand       | AMPK/IL-6, CRP, TNF-α    | STZ-induced DN rats     | Metformin (300 mg/kg/d, gavage.) from 3 days after STZ injection until the end of the study | Decreased blood glucose; restored MNCV; activated AMPK; reduced IL-6, CRP, and TNF-α |
| Cao             | AMPK/NF-κB               | STZ-induced DN rats     | Metformin (200 mg/kg/d, i.p.) for 6 days from the third week after STZ injection          | Attenuated mechanical allodynia; activated AMPK; reduced NF-κB                     |
| Haddad          | AMPK/CYP4A/20-HETE       | MKR nonobese T2DM male mice | Metformin (150 mg/kg/d, i.p.) for 13 weeks from 10 weeks after diabetes onset | Decreased blood glucose; corrected neural sensory and motor abnormalities; blunted oxidative stress and peripheral nerve injury; alleviated autophagy protein alterations triggered by hyperglycemia; |
| Ma              | AMPK/oxidative stress    | STZ-induced PDPN rats   | Metformin (300 mg/kg/d, i.p.) from 21 days after STZ injection until the end of the study | Inhibited mechanical hyperalgesia; increased paw withdrawal latency to heat and cold; activated AMPK and AMPK target genes (PGC-1α, Sirt-3, and nNOS); decreased malondialdehyde and glycation end-products; increased superoxide dismutase |
| García          | Rescued insulin resistance | Fructose-induced insulin resistance neuropathic pain rats | Metformin (50 mg/kg/d, po) for 4 weeks starting at 12 weeks after chronic fructose administration | Reversed fructose-induced tactile alodynia; reduced fructose-induced increased expression of GFAP; reversed fructose-induced downregulation of the insulin receptor β protein expression |
| Byrne           | /                        | High-fat diet/STZ induced diabetes rats | Metformin (200 mg/kg/d, po) from day 4 until day 40 after induced by STZ | Prevented reduction of mechanical withdrawal thresholds in high-fat diet/STZ rats; |
| Wang            | AMPK/TRPA1               | STZ-induced DN mice     | Metformin (10 ml; 50 mmol/L in saline, subcutaneous injection) for short-term treatment; metformin (250 mg/kg; 62.5 mg/ml in saline i.p.) for long-term treatment | Inhibited high-glucose-promoted TRPA1 activation; alleviated mechanical alldynia in diabetic mice |
| Huang           | AMPK/MGO                 | STZ-induced DN rats     | Metformin was incubated at 1200 mmol/L with methyl glyoxal (400 mmol/L) at 37°C for 3 h; metformin (250 mg/kg, subcutaneous injection once) at 4 weeks after STZ | Reduced the free MGO level by 99.4%; reduced MGO-induced acute flinching responses; blocked STZ-induced mechanical alldynia |

Abbreviations: 20-HETE, 20-hydroxyeicosatetraenoic acid; AMPK, adenosine monophosphate protein kinase; CRP, C-reactive protein; CYP, cytochrome P450; DN, diabetic neuropathy; GFAP, glial fibrillary acidic protein; IL-6, interleukin-6; MGO, methylglyoxal; MNCV, Motor nerve conduction velocities; NF-κB, nuclear factor-kappa B; PDPN, painful diabetic peripheral neuropathy; STZ, streptozotocin; T2DM, type 2 diabetes mellitus; TNF-α, tumor necrosis factor-α; TRPA1, transient receptor potential ankyrin 1.
DPN. Metformin attenuated mechanical allodynia through downregulating NF-κB expression in L4-6 DRG neurons, and the expression of NF-κB was controlled by P-AMPK.\(^5\)

Inhibition of oxidative stress through activating AMPK may be a beneficial effect of metformin. Oxidative stress is an important part in the development of diabetes complications.\(^39\) Increased lipid peroxidation such as malondialdehyde and glycation end products and decreased superoxide dismutase activity, which can be reversed by metformin, were observed in STZ-induced DPN rats.\(^28\) AMPK is closely related to oxidative stress, and its activation can ameliorate oxidative stress and protect cells from oxidative stress damage.\(^36,40,41\) Metformin activates AMPK and increases the expression of AMPK target proteins (PGC-1α, Sirt3, and nNOS) associated with DN.\(^28\) Metformin inhibited oxidative stress by activating AMPK, which may partly explain its effect on relieving hyperalgesia (including mechanical hyperalgesia, hot allodynia, and cold allodynia).\(^28\) CYP4A is a subgroup of cytochrome P450 (CYP) enzyme family, CYP4A \(ω\)-hydroxylase converts arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE).\(^42\) CYP enzyme is the main source of reactive oxygen species (ROS), and 20-HETE mediates inflammation and oxidation. The expression lever of CYP4A, 20-HETE, and ROS was increased in sciatic nerve tissues of MKR nonobese T2DM mice, both HET0016 (a specific 20-HETE synthase and/or CYP4A inhibitor) and metformin reduced ROS and corrected neural sensory and motor abnormalities of T2DM mice.\(^27\) In addition, metformin reduced the level of 20-HETE, and HET0016 restored the expression of P-AMPK, which suggested that CYP4A/20-HETE/AMPK mediate nerve damage through oxidative stress and an interaction existed between them.

2.1.2 | Regulate autophagy

Beclin-1 and LC3B, the key proteins of the autophagic response, significantly increased in the sciatic nerve of mice with diabetes and were also affected by CYP4A/20-HETE/AMPK.\(^27\) A cell-level study showed that high glucose increased autophagosome and LC3B in PC12 cells.\(^43\) Metformin can alleviate autophagy (decreased beclin-1 and LC3B expression in sciatic nerve) by activating CYP4A/20-HETE/AMPK pathological axis, saving peripheral nerve injury in diabetic mice.\(^27\) However, there are conflicting conclusions regarding autophagy in DN. The level of beclin-1 in sciatic nerve decreased in STZ-induced diabetic rats, and P-AMPK enhanced autophagy response by promoting autophagosome formation.\(^44\) Autophagy is a cellular process in which senescent or damaged organelles and proteins in the autophagosome are sequestered to recover their products and is also involved in the elimination of cells that undergo classic type 1 programmed cell death. Therefore, autophagy is generally considered to be a protective cellular response against various stressors and daily wear and tear. On the other hand, autophagy may also lead to a nonapoptotic cell death called type 2 programmed cell death.\(^45\) We hypothesize that the conflicting conclusions about autophagy may be due to the different models used in the studies.

2.1.3 | Regulate ion channel

Voltage-gated sodium channel Nav1.7 is selectively expressed in sensory and autonomic neurons and associated with excitation of nociceptive neurons.\(^46\) Pain can be relieved by downregulating NaV1.7 expression or using NaV1.7 blockers. Metformin enhanced the function of neuronal precursor cell expressed developmentally downregulated-4 type 2 (NEDD4-2, a ubiquitin protein ligase) by activating AMPK, then induced a decreased expression of NaV1.7, and ultimately reduced the excitability of nociceptive neurons.\(^6\)

In addition to expression level, the gated properties of NaV1.7 also affect the excitability of nociceptive neurons. Mitogen-activated protein kinase (MAPK) family is a pivotal signaling system with at least four pathways. Among them, the MAPK/ERK (extracellular-regulated kinase) pathway has been implicated in many cellular functions (including migration, differentiation, apoptosis, and senescence) and pathologies including pain.\(^47\) NaV1.7 is activated by directly phosphorylation by pERK1/2 (a phosphorylated ERK), and inhibition of pERK1/2 reduces the excitability of DRG neurons.\(^48\) The upstream activation mechanism of ERK signaling pathway may be related to the inactivation of AMPK,\(^49\) so metformin can reduce cell excitability by activating AMPK. Although this mechanism has not been directly validated in a diabetes model, it has been demonstrated in a model of neuropathic pain induced by chronic compression of the dorsal root ganglion and high-fat diet and in cell experiments.

The transient receptor potential ankyrin 1 (TRPA1) channel is a pain sensor mainly expressed in primary sensory neurons,\(^50\) which can be activated by accumulated methylglyoxal in hyperglycemia patients to facilitate PDPN.\(^51\) Studies have shown that TRPA1 can also be regulated by AMPK.\(^29\) TRPA1 is a transmembrane protein whose activity is determined by the expression level of plasma membrane. Metformin reduced the level of membrane-associated TRPA1 in DRG neurons cultured
with high glucose and alleviated mechanical allodynia in diabetic mice.\textsuperscript{29}

Metformin can also treat other types pain by activating AMPK. In mouse models of postoperative pain, activated AMPK negatively regulated mammalian target of rapamycin (mTOR) signaling pathway, preventing acute pain from transitioning to chronic pain.\textsuperscript{14} Activation of the mTOR/p70S6K pathway is involved in chronic pain caused by nerve injury or inflammation.\textsuperscript{52} AMPK inhibits the mTOR/p70S6K signaling pathway, thereby alleviating painful radiculopathies in lumbar disc herniation rat model and acute pain induced by oxaliplatin in rat models,\textsuperscript{9} which may be associated with inhibition of herniation plasticity.\textsuperscript{53}

\section*{2.2 | Remove methylglyoxal}

MGO is a reactive carbonyl compound produced by a nonenzymatic pathway of glucose metabolism and it has been reported to be associated with PDPN.\textsuperscript{54} Methylglyoxal spontaneously reacts with biopolymers to form advanced glycation end products (AGEs), and it mainly degraded by glyoxalase system, where glyoxalase I (Glo1) is the rate-limiting enzyme.\textsuperscript{55} Studies have shown that increased AGEs production and decreased GloI activity are conducive to the development of PDPN.\textsuperscript{56} Methylglyoxal may induce pain symptoms through oxidative stress,\textsuperscript{57} inflammatory stimulation\textsuperscript{58} and regulation ion channels (such as TRPA1,\textsuperscript{59,60} NaV1.8,\textsuperscript{30,61} and NaV1.7\textsuperscript{62}) and hyperpolarization–activated cyclic nucleotide-gated channel.\textsuperscript{63}

T2DM patients with metformin had lower plasma methylglyoxal levels, despite similar blood sugar levels.\textsuperscript{64,65} Metformin also reduced AGEs.\textsuperscript{66,67} Therefore, metformin is considered a potential drug for the treatment of PDPN, which has been confirmed in basic experiments.\textsuperscript{30}

Metformin can clear MGO in vivo and in vitro. When MGO was co-incubated with metformin, free MGO levels were reduced by more than 90%. When the incubation solution was injected into the hind paw of mice, no mechanical pain was observed. Systemic injection of metformin can effectively inhibit the pain induced by claw injection of MGO and significantly block STZ-induced mechanical pain.\textsuperscript{30} Intrathecal injection of metformin also significantly reduced the upregulated MGO in the dorsal horn and mechanical pain induced by bortezomib treatment, which may be related to RAGE/STAT3 signaling pathway.\textsuperscript{58} Metformin also reduced MGO-induced apoptosis by inhibiting oxidative stress in vivo and in vitro.\textsuperscript{69} Taken together, the data suggested that metformin, as an MGO scavenger, may serve as a disease reliever in PDPN.

\section*{2.3 | Reduce insulin resistance}

In recent years, the conclusion that hyperglycemia is the main cause of diabetic neuropathy has been challenged by the research results. Evidence suggested that peripheral neuropathy is also present in normoglycemic patients with metabolic syndrome and in a progenitor state prior to the establishment of T2DM.\textsuperscript{70,71} Insulin resistance (IR) is a condition in which the efficiency of insulin in promoting glucose uptake and utilization is reduced and in which the body compensates by producing too much insulin to maintain blood sugar stability, eventually leading to hyperinsulinemia.\textsuperscript{72}

Evidence for IR affecting nociception is as follows: (1) Insulinemia itself or its consequences play a role in mechanistic nociceptive injury. Chronic fructose treatment increased plasma insulin level and caused hyperalgesia and abnormal tactile pain without a significant increase of blood glucose levels.\textsuperscript{23} Compared with the control group, mechanical pain thresholds and the serum insulin level were decreased in both hyperglycemic and normal-glycemic rats after STZ treatment, but there was no statistical difference in blood glucose between two groups.\textsuperscript{73} (2) IR is associated with altered nociception. The homeostatic model assessment for insulin resistance index is an indicator of steady state beta cell function and insulin sensitivity, and its increase is associated with tactile allodynia and chemical hyperalgesia.\textsuperscript{23} (3) The effect on nociception may be because of insulin receptor expression or signal transduction related events rather than hyperglycemia. In the early course of nociceptive dysfunction, IR signal impairment in peripheral nerves was observed, which manifested decreased phosphorylation of insulin receptors and Akt protein.\textsuperscript{74,75} Clinical trials have also shown that people with IR are significantly more likely to have pain.\textsuperscript{70,76}

Metformin, an insulin sensitizer, reversed tactile pain and downregulated insulin receptor β in fructose-induced IR rats with neuropathic pain. Metformin reversed the upregulation of GFAP (astrocyte activation markers), ASIC3 (acid-sensing ion channel 3), and anoctamin-1 (an ionic channel involved in the nociceptive processing) in DRG of fructose induced IR rats.\textsuperscript{23} The mechanism of metformin treating PDPN by reducing IR remains further studied.

\section*{3 | ADVERSE REACTIONS IN CLINICAL APPLICATION OF METFORMIN}

According to the current clinical experience and data of metformin, there are few serious safety concerns. Rare
and mild side effects such as hypoglycemia, gastrointestinal side effects (typically nausea, vomiting, or diarrhea), impaired liver and kidney function, and heart failure can be effectively avoided by adjusting dosage and form. In addition, it is worth noting that metformin affected the status of vitamin B1, vitamin B12, vitamin D, folic acid, and magnesium and it interfered with the microbiome. Vitamin B12 deficiency can cause neurological dysfunction (such as peripheral and autonomic neuropathy, painful neuropathy) and accelerate the progression of DN. Therefore, we focused on the effects of metformin and vitamin B12 on neurological.

Since 1971, when malabsorption of vitamin B12 in diabetic patients with metformin was first reported, numerous clinical trials and meta-analyses have confirmed the association between metformin and low vitamin B12 levels. Vitamin B12 is found in foods as a protein-binding form and released under the action of gastric acid pepsin and trypsin after entering the digestive tract. Then the free vitamin B12 is bound by the intrinsic factor (IF, a glycosylated protein secreted by gastric parietal cells) forming IF-vitamin B12 complex, which is eventually absorbed in the ileum. Metformin is the main cause of vitamin B12 deficiency in T2DM patients and may be caused by the following mechanisms: (1) bacterial overgrowth caused by changes in the motility of the small intestine, (2) reduced vitamin B12 absorption due to changes of IF levels, and (3) inhibition of calcium-associated vitamin B12-IF complex absorption in the terminal ileum.

Many clinical studies have investigated the relationship between metformin-induced vitamin B12 deficiency and PDPN, but they have reached inconsistent conclusions. In some cross-sectional studies, T2DM patients were divided into metformin and metformin-free groups based on metformin medication history. Results showed a higher incidence of vitamin B12 deficiency and a higher incidence of neuropathy in the metformin group or no different than in the non-metformin group. Other studies included only T2DM patients with a history of metformin use, dividing them into vitamin B12 deficient or normal groups based on their serum vitamin B12 concentrations. There was no difference in the incidence of neuropathy between the two groups in these studies. There is also a study supporting that metformin-treated T2DM patients have a lower prevalence of neuropathy than non-metformin-treated T2DM patients.

In addition to these two grouping methods, researchers discussed the influence of metformin on DPN from other perspectives. We summarized these studies in Table 2. Russo et al found that 30% metformin-treated T2DM patients had neuropathy, and there was no difference in vitamin B12 levels between the neuropathy group and the normal group. Khalaf reported a 29% incidence of vitamin B12 deficiency and a 46% incidence of neuropathy among T2DM patients with metformin, but vitamin B12 concentration was not associated with the incidence of peripheral neuropathy. Furthermore, a randomized, double-blind, placebo-controlled trial demonstrated that oral vitamin B12 (methyl cobalamin) 1000 μg/day for one year increased plasma vitamin B12 levels and improved all neurophysiological parameters, sudomotor function, pain score, and quality of life. This study involved 90 T2DM patients taking metformin for at least 4 years with DN, which indirectly demonstrates a link between metformin, vitamin B12 deficiency, and neuropathy. However, a meta-analysis found no significant association between the risk of neuropathy and metformin use in diabetic patients, though a higher risk of vitamin B12 deficiency in patients with metformin. This result may be because of the heterogeneity of the included studies, such as inconsistencies of diagnostic criteria for neuropathy and metformin exposure time, so more exploration is needed on the relationship between metformin-induced vitamin B12 deficiency and neuropathy.

Anemia is also a potential consequence of vitamin B12 deficiency, which occurs much later than neuropathy. Anemia was not the primary objective of most studies, and metformin exposure was not long enough to reveal a significant association between metformin use and anemia. A long-term study showed patients at high risk for diabetes who took metformin for 5 years had a significantly higher prevalence of anemia than those who did not. More long-term studies are needed in the future to explain the association between anemia and metformin use.

4 | SEX DIFFERENCES IN METFORMIN ON PAIN

A large body of studies have clearly suggested that men and women respond to pain differently, as well as to pharmacological pain interventions. There was no difference in the prevalence of diabetic neuropathy between different gender, but female may be a risk factor of PDPN. In some mouse models of pain, the pain relief effect of metformin is also sexually dimorphic. Metformin reduced spared nerve injury-induced mechanical hypersensitivity and cold-induced mechanical hypersensitivity and reversed the activation of microglia in the spinal cord in male mice instead of female mice. It was observed that metformin reduced incision-induced mechanical hypersensitivity and blocked hyperalgesia initiation only in male mice. Sex hormones may influence the effect of metformin on neuropathic pain. Metformin is a water-soluble drug that requires the help of the organic cation transporter (OCT2) to cross the cell membrane. OCT2 shows sexual dimorphic expression in many tissues of many species, with...
TABLE 2  Clinical studies involving metformin, vitamin B12 deficiency, and diabetic neuropathy.

| Study          | Characteristics of patients                                                                 | Duration of diabetes(years) | HbA1c levels(%) | Results of prevalence of vitamin B12 deficiency | Results of prevalence of neuropathy |
|----------------|---------------------------------------------------------------------------------------------|-----------------------------|-----------------|-----------------------------------------------|-----------------------------------|
| Singh A K.     | T2DM patients were divided into metformin exposed group and nonmetformin exposed group       | /                           | MET: 8.2 ± 1.02  | MET: 21.4%                                     | MET: 53.6%                        |
|                |                                               |                             | NMET: 8.4 ± 0.8  | NMET: 5.7%                                     | NMET: 2.3%                        |
|                |                                               |                             | p < .05          |                                               | (p < .05)                         |
| de Groot-Kamphuis | T2DM patients were divided into metformin exposed group and nonmetformin exposed group     | MET: 12.1 (7.6–17.9)        |                 | MET: 14.1%                                     | MET: 17.4%                        |
|                |                                               | NMET: 17.9 (12.1–23.9)      |                 | NMET: 4.4%                                     | NMET: 28.1%                       |
|                |                                               |                             | p < .05          |                                               | (p < .05)                         |
| Wile           | T2DM patients were divided into metformin exposed group and nonmetformin exposed group       | MET: 5.5 ± 3.3              |                 | MET: 31%                                       | MET: 10%                          |
|                |                                               | NMET: 4.7 ± 2.9             |                 | NMET: 3%                                       | NMET: 5%                          |
|                |                                               |                             | p < .05          |                                               | (p < .05)                         |
| Hashem         | T2DM patients with DPN were divided into metformin exposed group and nonmetformin exposed group | MET: 5.9 ± 4.3              |                 | MET: 25%                                       | There was a significant inverse relationship between DPN severity and cobalamin level (r = −0.81, p < .05) |
|                |                                               | NMET: 3.9 ± 4.8             |                 |                                               |                                   |
| Aroda          | persons at high risk for T2DM were divided into metformin exposed group and nonmetformin exposed group | /                           | MET: 5.9 ± 0.64  | MET: 37%                                       | MET: 9.9%                         |
|                |                                               |                             | NMET: 6.02 ± 0.7 | NMET: 20%                                      | NMET: 9.9%                        |
|                |                                               |                             | p < .05          |                                               | (p > .05)                         |
| Roy            | T2DM patients without DPN were divided into metformin exposed group and nonmetformin exposed group | ≤5 years                    | MET: 7.09 ± 0.28 | MET: 306.31 ± 176.70 mg/dl                     | MET: 54.28%                       |
|                |                                               |                             | NMET: 7.035 ± 0.35| NMET: 627.54 ± 168.32 mg/dl                    | NMET: 28.57%                      |
|                |                                               |                             | p < .01          |                                               | (p < .05)                         |
| Khalaf         | Metformin-treated T2DM patients were divided into vitamin B12-deficient and normal groups. | 8.67 ± 5.98                | 9.8 ± 1.8       | Prevalence of vitamin B12 deficiency was 29%   | 46% of all patients had peripheral neuropathy but vitamin B12 concentration was not associated with the incidence of peripheral neuropathy |
| Ahmed          | Metformin-treated T2DM patients were divided into vitamin B12-deficient and normal groups. | LVB: 12 (6.85–17)          | LVB: 7.4 (6.3–9.6) | Prevalence of vitamin B12 deficiency was 28.1% | MET: 32.3%                        |
|                |                                               | NVB: 9 (5–16)               | NVB: 9.4 (7.5–11.2) |                                               | NMET: 36.8% (p > .05).           |
| Biemans        | Metformin-treated T2DM patients were divided into vitamin B12-deficient and normal groups. | LVB: 9.3 ± 5.2              | LVB: 7.3 ± 1.1  | Prevalence of cobalamin deficiency was 28.1%; Prevalence of holoTCII deficiency was 3.9% | Neuropathy occurred more frequently in cobalamin-deficient (26.7 vs. 21.8%, p > .05) and holoTCII-deficient patients (29.4 vs. 20.6%, p > .05) compared with normal groups; however, the differences were not significant |
|                |                                               | NVB: 8.5 ± 6.3              | NVB: 7.4 ± 1.2   |                                               |                                   |
| Russo          | Metformin-treated T2DM patients were divided into neuropathy and normal groups                | T2DM with DPN: 13.6 ± 10.1 | T2DM with DPN: 7.7 ± 1.5  | T2DM with DPN: 621.2 ± 267.3 pg/ml            | Metformin treatment was associated with a mild decline in vitamin B12 levels, but not DPN |
|                |                                               | T2DM without DPN: 10.9 ± 8.6| T2DM without DPN: 7.3 ± 1.4  | T2DM without DPN: 598.9 ± 316.2 pg/ml, p > .01 |                                   |

Note: Data are expressed as mean ± SD, median (25–75 percentile) or n (%).

Abbreviation: cobalamin, vitamin B12; DPN, diabetic peripheral neuropathy; holoTCII, holo-transcobalamin; LVB, low vitamin B12; MET, metformin exposed group; NMET, nonmetformin exposed group; NVB, normal vitamin B12; T2DM, type 2 diabetes mellitus.
higher expression in males,\textsuperscript{105} which is related to androgen regulation.\textsuperscript{106} However, Iyang et al thought the sex difference cannot be explained by metformin pharmacokinetics because metformin levels in the plasma and brain of female mice are higher than those of male mice.\textsuperscript{14} Metformin is the only AMPK activator with sex-specific effects, sex differences may be owing to a link in the AMPK pathway. However, another paper does not support this view.\textsuperscript{9} On the contrary, they reported that metformin had the same effect on male and female mice after lumbar disc puncture, although mechanical pain was more severe in female mice before treatment.

According to a study of data from a UK biobank, T2DM patients are more likely to report musculoskeletal pain in shoulder, neck, knee, or hip, particularly among women.\textsuperscript{107} The development of musculoskeletal pain may be related to the production of AGEs, leading to an inflammatory metabolic environment and oxidative stress, reducing connective tissue elasticity and weakening tendons.\textsuperscript{108} A follow-up study by the same team said diabetics with metformin were less likely to have musculoskeletal pain, especially in women.\textsuperscript{109} We did not find any other clinical studies on gender differences in metformin analgesia. Whether there is a gender difference in the analgesic effect of metformin needs further study.

5 DISCUSSION

Metformin is a first-line treatment for T2DM patients, and it is also used to treat polycystic ovary syndrome, hyperlipidemia, coronary artery disease, obesity, and a variety of kidney diseases such as acute kidney diseases, diabetic kidney disease, urolithiasis, renal cell carcinoma, end-stage renal disease, and renal fibrosis.\textsuperscript{110,111} There is considerable evidence that metformin also has beneficial effects on neuroprotection and hyperalgesia.\textsuperscript{5,112} Metformin can reduce inflammatory response and oxidative stress and regulate autophagy response and the activation or expression of NaV1.7 and TRPA1 channels to play analgesic and antihyperalgesia roles by activating AMPK. Metformin’s analgesia is also partially explained by the reduction in MGO and IR. These results provide a certain basis for metformin to be a potential drug in the treatment of PDN.

However, there are discrepancies between clinical data and preclinical data. Only one study showed a lower frequency of neuropathy in patients using metformin,\textsuperscript{90} and others showed a similar or higher\textsuperscript{99,91,94,95} incidence of neuropathy in metformin patients. Vitamin B12 deficiency caused by metformin was thought to be associated with a higher incidence of neuropathy. Studies have generally shown metformin was associated with lower plasma vitamin B12 concentrations,\textsuperscript{113,114} but the association between metformin-induced vitamin B12 deficiency and DN remains controversial because of confounding factors including age, study environment, duration of diabetes, and dose and duration of metformin in clinical studies. Neuropathy associated with vitamin B12 deficiency is difficult to distinguished from DPN in T2DM patients. Therefore, the conclusion that a higher frequency of neuropathy is associated with metformin-induced vitamin B12 deficiency is controversial. It has also been reported that metformin reduces only the level of nonfunctional plasma vitamin B12 but increases vitamin B12 accumulation in the liver.\textsuperscript{115} Low plasma B12 levels in metformin-treated patients do not reflect impaired B12 status but rather altered tissue distribution and metabolism of vitamin B12. Metformin was associated with improved intracellular vitamin B12 metabolism despite low plasma vitamin B12, which has been clinically confirmed. Compared with T2DM patients without metformin, patients on metformin have a comparable red blood cell B12, a slightly lower methylmalonic acid, and better methylation index despite a low B12 plasma status,\textsuperscript{116} which suggested that metformin treatment was associated with improved intracellular vitamin B12 metabolism. Intracellular vitamin B12, rather than plasma vitamin B12, acts as a cofactor for enzymes that play a critical role in neuroprotection,\textsuperscript{117} so metformin-induced plasma vitamin deficiency may have little effect on the DPN.

Even though the association between diabetic neuropathy and metformin-induced vitamin B12 deficiency is unclear, as a matter of best safety, we recommend regular screening for serum vitamin B12 levels and peripheral neuropathy in T2DM patients on long-term metformin use. However, because of financial and medical constraints, regular testing of vitamin levels is a burden for many patients, and researchers have suggested that the Metformin Usage Index (MUI) be used as a risk assessment tool to assess vitamin B12 deficiency in T2DM patients. MUI is the product of the dose (mg) of metformin used and its duration (years) divided by 1000, and patients have a high risk of vitamin B12 deficiency when the MUI>5.\textsuperscript{118}

There are still some limitations in our study. Contrary to the results of basic studies, metformin does not provide significant neuroprotection in patients with T2DM in clinical practice, which may be because of vitamin B12 deficiency. The clinical and basic researches have different concerns. Basic researches focused on metformin’s neuroprotective effects and mechanisms, whereas clinical studies focused on vitamin B12 deficiency. The shorter duration of metformin intervention in the primary study may be responsible for the lack of reports of vitamin B12 deficiency and associated adverse events. Metformin combined with vitamin B12 may be
beneficial for diabetic neuropathy. Vitamin B12 in combination with metformin in T2DM patients reduced the incidence of peripheral neuropathy compared with metformin alone, but the trial did not set a control group without metformin. Further clinical trials are needed to investigate the neuroprotective effects of metformin. In addition, most studies have been conducted in patients with type 2 diabetes, whereas metformin’s effect on neuropathy in patients with type 1 diabetes is poorly understood.

In conclusion, the therapeutic effect of metformin on DPN has been confirmed in many basic studies, and more and more studies have been conducted on its mechanism. However, clinical studies have focused on whether metformin-induced vitamin B12 deficiency exacerbates neuropathy. This contradiction is worthy of attention and research. More clinical studies are needed in the future to observe the efficacy and safety of metformin in the treatment of diabetic neuropathy.

AUTHOR CONTRIBUTIONS
J.W. conducted the study and wrote the text. S.J. gave research and writing guidance and approved the final version. Yanling Wei revised granner and technical terms to make the article more accurate. Meiyan Huang and Peng Wang were the main producer of figures and tables.

ACKNOWLEDGEMENTS
None.

FUNDING INFORMATION
No external funding.

CONFLICT OF INTEREST
The authors declare that they have no competing interest.

ORCID
Juechun Wei @ https://orcid.org/0000-0001-5021-1912
Yanling Wei @ https://orcid.org/0000-0003-2573-7204
Meiyan Huang @ https://orcid.org/0000-0001-9570-2475
Peng Wang @ https://orcid.org/0000-0002-7014-526X
Shushan Jia @ https://orcid.org/0000-0002-6725-0392

REFERENCES
1. Selvarajah D, Kar D, Khunti K, et al. Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early intervention. Lancet Diabetes Endocrinol. 2019;7:938-948.
2. Abbott CA, Malik RA, van Ross ERE, Kulkarni J, Boulton AJM. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the UK. Diabetes Care. 2011;34:2220-2224.
3. Jensen TS, Karlsson P, Gylfadottir SS, et al. Painful and non-painful diabetic neuropathy, diagnostic challenges and implications for future management. Brain. 2021;144:1632-1645.
4. Baeza-Flores GDC, Guzmán-Priego CG, Parra-Flores LI, Murbartiján J, Torres-López JE, Granados-Soto V. Metformin: a prospective alternative for the treatment of chronic pain. Front Pharmacol. 2020;11:558474.
5. Cao X-J, Wu R, Qian H-Y, et al. Metformin attenuates diabetic neuropathic pain via AMPK/γ-tubulin signaling pathway in dorsal root ganglion of diabetic rats. Brain Res. 2021;1772:147663.
6. Defu A-F, Chu Sin Chung P, Laedermann CJ, et al. The anti-diabetic drug metformin regulates voltage-gated Sodium Channel Na1.7 via the ubiquitin-ligase NEDD4-2. eNeuro. 2022;9(2):0409-0421.
7. Habimantuqolu A, Mohammadzadeh M, Taghizadehghalehjoughi A, et al. The analgesic effect of metformin on paclitaxel-induced neuropathic pain model in rats: by considering pathological results. J Cancer Res Ther. 2020;16:34-39.
8. Liu Y, Zhou G, Xu N. Effect of metformin nanoparticle-mediated Thioredoxin interacting protein expression on Oxaliplatin-induced peripheral neuralgia. J Nanosci Nanotechnol. 2020;20:6123-6132.
9. Liu Y, Li J, Li H, et al. AMP-activated protein kinase activation in dorsal root ganglion suppresses mTOR/p70S6K signaling and alleviates painful radiculopathies in lumbar disc herniation rat model. Spine (Phila Pa 1976). 2019;44:E865-E872.
10. Das V, Krov J, Moric M, McCarthy RJ, Buvanendran A. AMP-activated protein kinase (AMPK) activator drugs reduce mechanical allodynia in a mouse model of low back pain. Reg Anesth Pain Med. 2019;44:1010-1014.
11. Wang Y, Hussain SM, Wluka AE, et al. Association between metformin use and disease progression in obese people with knee osteoarthritis: data from the osteoarthritis initiative-a prospective cohort study. Arthritis Res Ther. 2019;21:127.
12. Li J, Zhang B, Liu W-X, et al. Metformin limits osteoarthritis development and progression through activation of AMPK signalling. Ann Rheum Dis. 2020;79:635-645.
13. Das V, Krov J, Moric M, McCarthy RJ, Buvanendran A. Antihyperalgesia effect of AMP-activated protein kinase (AMPK) activators in a mouse model of postoperative pain. Reg Anesth Pain Med. 2019;44:781-786.
14. Inyang KE, Burton MD, Szabo-Pardi T, et al. Indirect AMP-activated protein kinase initiators prevent incision-induced hyperalgesia and Block Hyperalgesic priming, whereas positive allosteric modulators Block only priming in mice. J Pharmacol Exp Ther. 2019;371:138-150.
15. Augusto PSA, Matsui TC, Braga AV, et al. Metformin effect in models of inflammation is associated with activation of ATP-dependent potassium channels and inhibition of tumor necrosis factor-α production. Inflammopharmacology. 2022:30:233-241.
16. Guzmán-Priego CG, Méndez-Mena R, Baños-González MA, Araiza-Saldaña CI, Castaña-Corral G, Torres-López JE. Antihyperalgesic effects of indomethacin, ketorolac, and Metamizole in rats: effects of metformin. Drug Dev Res. 2017;78:91-104.
17. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-820.
18. Bierhaus A, Fleming T, Stoyanov S, et al. Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and...
causes hyperalgesia in diabetic neuropathy. *Nat Med.* 2012;18: 926-933.

19. Yousef Khan F, Yousif AB, Suliman A, et al. Association of vitamin B12 deficiency with metformin use in patients with type 2 diabetes treated in the largest tertiary care hospital in Qatar. *Qatar Med J.* 2021;2021:39.

20. Lohmann AE, Liebman MF, Brien W, et al. Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32. *Breast Cancer Res Treat.* 2017;164:371-378.

21. Rena G, Pearson ER, Sakamoto K. Molecular mechanism of action of metformin: old or new insights? *Diabetologia.* 2013;56:1898-1906.

22. Tesfaye S, Boulton AJM, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. *Diabetes Care.* 2010;33:2285-2293.

23. Garcia G, Gutiérrez-Lara EL, Centurión D, Granados-Soto V, Murbartían J. Fructose-induced insulin resistance as a model of neuropathic pain in rats. *Neuroscience.* 2019;404:233-245.

24. Brouwers O, Niessen PM, Ferreira I, et al. Overexpression of glyoxalase-I reduces hyperglycemia-induced levels of advanced glycation end products and oxidative stress in diabetic rats. *J Biol Chem.* 2011;286:1374-1380.

25. Byrne FM, Cheetham S, Vickers S, Chapman V. Characterisation of pain responses in the high fat diet/streptozotocin model of diabetes and the analgesic effects of antidiabetic treatments. *J Diabetes Res.* 2015;2015:752481.

26. Hasanvand A, Amini-Khoei H, Hadian M-R, et al. Anti-inflammatory effect of AMPK signaling pathway in rat model of diabetic neuropathy. *Inflammopharmacology.* 2016;24:207-219.

27. Haddad M, Eid S, Harb F, et al. Activation of 20-HETE synthase triggers oxidative injury and peripheral nerve damage in type 2 diabetic mice. *J Pain.* 2022;23:1371-1388.

28. Ma J, Yu H, Liu J, Chen Y, Wang Q, Xiang L. Metformin attenuates hyperalgesia and allodynia in rats with painful diabetic neuropathy induced by streptozotocin. *Eur J Pharmacol.* 2015;764:599-606.

29. Wang S, Kobayashi K, Kagure Y, et al. Negative regulation of TRPA1 by AMPK in primary sensory neurons as a potential mechanism of painful diabetic neuropathy. *Diabetes.* 2018;67:98-109.

30. Huang Q, Chen Y, Gong N, Wang Y-X. Methylglyoxal mediates streptozotocin-induced diabetic neuropathic pain via activation of the peripheral TRPA1 and Nav1.8 channels. *Metabolism.* 2016;65:463-474.

31. Russe OQ, Möser CV, Kynast KL, et al. Activation of the AMP-activated protein kinase reduces inflammatory nociception. *J Pain.* 2013;14:1330-1340.

32. Herzig S, Shaw RJ. AMPK: guardian of metabolism and mitochondrial homeostasis. *Nat Rev Mol Cell Biol.* 2018;19:121-135.

33. Woods A, Johnstone SR, Dickerson K, et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. *Curr Biol.* 2003;13:2004-2008.

34. Steinberg GR, Carl ing D. AMP-activated protein kinase: the current landscape for drug development. *Nat Rev Drug Discov.* 2019;18:527-551.

35. Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. *Science.* 2005;310:1642-1646.

36. Alcocer-Gómez E, Garrido-Maraver J, Bullón P, et al. Metformin and caloric restriction induce an AMPK-dependent restoration of mitochondrial dysfunction in fibroblasts from fibromyalgia patients. *Biochim Biophys Acta.* 2015;1852:1257-1267.

37. Yorek MA, Wiese TJ, Davidson EP, et al. Reduced motor nerve conduction velocity and Na(+)-K(+)-ATPase activity in rats maintained on L-fucose diet. Reversal by myo-inositol supplementation. *Diabetes.* 1993;42:1401-1406.

38. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. *Cold Spring Harb Perspect Biol.* 2009;1:a001651.

39. Eid AA, Ford BM, Block K, et al. AMP-activated protein kinase (AMPK) negatively regulates Nox4-dependent activation of p53 and epithelial cell apoptosis in diabetes. *J Biol Chem.* 2010;285:37503-37512.

40. Dong G-Z, Lee J-H, Ki SH, et al. AMPK activation by isorhamnetin protects hepatocytes against oxidative stress and mitochondrial dysfunction. *Eur J Pharmacol.* 2014;740:634-640.

41. Yang JH, Shin BY, Han JY, et al. Isorhamnetin protects against oxidative stress by activating Nrf2 and inducing the expression of its target genes. *Toxicol Appl Pharmacol.* 2014;274:293-301.

42. Chen L, Tang S, Zhang FF, et al. CYP4A/20-HETE regulates ischemia-induced neovascularization via its actions on endothelial progenitor and preexisting endothelial cells. *Am J Physiol Heart Circ Physiol.* 2019;316:H1468-H1479.

43. Nazarenezhad S, Rahmati M, Shayannia A, Abbasi Z, Salehi M, Khaksari M. Nesfatin-1 protects PC12 cells against high glucose-induced cytotoxicity via inhibiting oxidative stress, autophagy and apoptosis. *Neurotoxicology.* 2019;74:196-202.

44. Yerra VG, Areti A, Kumar A. Adenosine monophosphate-activated protein kinase abates Hyperglycaemia-induced neuronal injury in experimental models of diabetic neuropathy: effects on mitochondrial biogenesis, autophagy and neuroinflammation. *Mol Neurobiol.* 2017;54:2301-2312.

45. Gonzalez CD, Lee M-S, Marchetti P, et al. The emerging role of autophagy in the pathophysiology of diabetes mellitus. *Autophagy.* 2011;7:2-11.

46. Bennett DLH, Woods CG. Painful and painless channelopathies. *Lancet Neurol.* 2014;13:587-599.

47. Ji R-R, Strichartz G. Cell signaling and the genesis of neuropathic pain. *Sci STKE.* 2004;2004:reE14.

48. Stamboulan S, Choi J-S, Ahn H-S, et al. ERK1/2 mitogen-activated protein kinase phosphorylates sodium channel Na(v)1.7 and alters its gating properties. *J Neurosci.* 2010;30:1637-1647.

49. Fu C-N, Wei H, Gao W-S, Song S-S, Yue S-W, Qu Y-J. Obesity and caloric restriction induce an AMPK-dependent restoration of mitochondrial dysfunction in fibroblasts from fibromyalgia patients. *Biochim Biophys Acta.* 2015;1852:1257-1267.
pathway reduces neuropathic pain in mice. *Pain*. 2011;152:2582-2595.
53. Ling Y-Z, Li Z-Y, Ou-Yang H-D, et al. The inhibition of spinal synaptic plasticity mediated by activation of AMP-activated protein kinase signaling alleviates the acute pain induced by oxaliplatin. *Exp Neurol*. 2017;288:85-93.
54. Barragán-Iglesias P, Kuhn J, Vidal-Cantú GC, et al. Activation of the integrated stress response in nociceptors drives methylglyoxal-induced pain. *Pain*. 2019;160:160-171.
55. Jack M, Wright D. Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy. *Transl Res*. 2012;159:355-365.
56. Skapare E, Konrade I, Liepinsh E, et al. Association of reduced glyoxalase 1 activity and painful peripheral diabetic neuropathy in type 1 and 2 diabetes mellitus patients. *J Diabetes Complications*. 2013;27:262-267.
57. Andersson DA, Gentry C, Moss S, Bevan S. Transient receptor potential A1 is a sensory receptor for multiple products of oxidative stress. *J Neurosci*. 2008;28:2485-2494.
58. Düll MM, Riegel K, Tappenbeck J, et al. Methylglyoxal causes pain and hyperalgesia in human through C-fiber activation. *Pain*. 2019;160:2497-2507.
59. Viisanen H, Chapman H, Wei H, et al. Pronociceptive effects induced by cutaneous application of a transient receptor potential ankyrin 1 (TRPA1) channel agonist methylglyoxal in diabetic animals: comparison with tunicamycin-induced endoplasmic reticulum stress. *J Physiol Pharmacol*. 2016;67:587-594.
60. Andersson DA, Gentry C, Light E, et al. Methylglyoxal evokes pain by stimulating TRPA1. *PLoS One*. 2013;8:e77986.
61. Rondón LJ, Privat AM, Daulhac L, et al. Magnesium attenuates chronic hypersensitivity and spinal cord NMDA receptor phosphorylation in a rat model of diabetic neuropathic pain. *J Physiol*. 2010;588:4205-4215.
62. Cheng R-X, Feng Y, Liu D, et al. The role of Na1.7 and methylglyoxal-mediated activation of TRPA1 in itch and hypoalgesia in a murine model of type 1 diabetes. *Theranostics*. 2019;9:4287-4307.
63. Shimatani Y, Nodera H, Osaki Y, et al. Uregulation of axonal HCN current by methylglyoxal: potential association with diabetic polyneuropathy. *Clin Neurophysiol*. 2015;126:2226-2232.
64. Beisswenger PJ, Howell SK, Touchette AD, Lal S, Szewergold BS. Metformin reduces systemic methylglyoxal levels in type 2 diabetes. *Diabetes*. 1999;48:198-202.
65. Memon MA, Khan RN, Riaz S, Ain QU, Ahmed M, Kumar N. Methylglyoxal and insulin resistance in berberine-treated type 2 diabetic patients. *J Res Med Sci*. 2018;23:110.
66. Rahbar S, Natarajan R, Yerneni K, Scott S, Gonzales N, Nadler JL. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. *Clin Chim Acta*. 2000;301:65-77.
67. Machado AP, Pinto RS, Moysés ZP, Nakandakare ER, Quintão ECR, Passarelli M. Aminoguanidine and metformin prevent the reduced rate of HDL-mediated cell cholesterol efflux induced by formation of advanced glycation end products. *Int J Biochem Cell Biol*. 2006;38:392-403.
68. Wei J-Y, Liu C-C, Ouyang H-D, et al. Activation of RAGE/-STAT3 pathway by methylglyoxal contributes to spinal central sensitization and persistent pain induced by bortezomib. *Exp Neurol*. 2017;296:74-82.
69. Wang G, Wang Y, Yang Q, et al. Metformin prevents methylglyoxal-induced apoptosis by suppressing oxidative stress in vitro and in vivo. *Cell Death Dis*. 2022;13:29.
70. Kazamel M, Stino AM, Smith AG. Metabolic syndrome and peripheral neuropathy. *Muscle Nerve*. 2021;63:285-293.
71. Smith AG, Rose K, Singleton JR. Idiopathic neuropathy patients are at high risk for metabolic syndrome. *J Neurol Sci*. 2008;273:25-28.
72. Shanik MH, Xu Y, Skrha J, Dankner R, Zick Y, Roth J. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? *Diabetes Care*. 2008;31(Suppl 2):S262-S268.
73. Romanovsky D, Hastings SL, Stimers JR, Dobretsov M. Relevance of hyperglycemia to early mechanical hyperalgesia in streptozotocin-induced diabetes. *J Peripher Nerv Syst*. 2004;9:62-69.
74. Sugimoto K, Rashid IB, Shoji M, Suda T, Yasujima M. Early changes in insulin receptor signaling and pain sensation in streptozotocin-induced diabetic neuropathy in rats. *J Pain*. 2008;9:237-245.
75. Zhai X, Sun C, Rong P, et al. A correlative relationship between chronic pain and insulin resistance in Zucker fatty rats: role of downregulation of insulin receptors. *J Pain*. 2016;17:404-413.
76. Pappolla MA, Manchikanti L, Candido KD, et al. Insulin resistance is associated with central pain in patients with fibromyalgia. *Pain Physician*. 2021;24:175-184.
77. Flory J, Lipska K. Metformin in 2019. *Jama*. 2019;321:1926-1927.
78. Wakeman M, Archer DT. Metformin and micronutrient status in type 2 diabetes: does polypharmacy involving acid-suppressing medications affect vitamin B12 levels? *Diabetes Metab Syndr Obes*. 2020;13:2093-2108.
79. Ahmed MA. Metformin and vitamin B12 deficiency: where do we stand? *J Pharm Pharm Sci*. 2016;19:382-398.
80. Tomkin GH, Hadden DR, Weaver JA, Montgomery DA. Vitamin-B12 status of patients on long-term metformin therapy. *Br Med J*. 1971;2:685-687.
81. Yang W, Cai X, Wu H, Ji L. Associations between metformin use and vitamin B(12) levels, anemia, and neuropathy in patients with diabetes: a meta-analysis. *J Diabetes*. 2019;11:729-743.
82. Kim J, Ahn CW, Fang S, Lee HS, Park JS. Association between metformin dose and vitamin B12 deficiency in patients with type 2 diabetes. *Medicine*. 2019;98:e17918.
83. Kanti G, Anadol-Schmitz E, Bobrov P, et al. Vitamin B12 and folate concentrations in recent-onset type 2 diabetes and the effect of metformin treatment. *J Clin Endocrinol Metab*. 2020;105:e2222-e2231.
84. de Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. *BMJ*. 2010;340:c2181.
85. Chapman LE, Darling AL, Brown JE. Association between metformin and vitamin B12 deficiency in patients with type 2 diabetes: a systematic review and meta-analysis. *Diabetes Metab*. 2016;42:316-327.
86. Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term metformin use and vitamin B12 deficiency in the diabetes prevention program outcomes study. *J Clin Endocrinol Metab*. 2016;101:1754-1761.
87. Al Saeed RR, Baraja MA. Vitamin B12 deficiency in patients with type 2 diabetes mellitus using metformin and the associated factors in Saudi Arabia. *Saudi Med J*. 2021;42:161-165.
88. Kozyraki R, Cases O. Vitamin B12 absorption: mammalian physiology and acquired and inherited disorders. Biochimie. 2013;95:1002-1007.

89. Singh AK, Kumar A, Karmakar D, Jha RK. Association of B12 deficiency and clinical neuropathy with metformin use in type 2 diabetes patients. J Postgrad Med. 2013;59:253-257.

90. de Groot-Kamphuis DM, van Dijk PR, Groenier KH, Houweling ST, Bilo HJG, Kleefstra N. Vitamin B12 deficiency and the lack of its consequences in type 2 diabetes patients using metformin. Neth J Med. 2013;71:386-390.

91. Wile DJ, Toth C. Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. Diabetes Care. 2010;33:156-161.

92. Ahmed MA, Muntingh G, Rheeder P. Vitamin B12 deficiency in metformin-treated type-2 diabetes patients, prevalence and association with peripheral neuropathy. BMC Pharmacol Toxicol. 2016;17:44.

93. Biemans E, Hart HE, Rutten GEHM, Cuellar Renteria VG, Kooijman-Buiting AMJ, Beulens JWJ. Cobalamin status and its relation with depression, cognition and neuropathy in patients with type 2 diabetes mellitus using metformin. Acta Diabetol. 2015;52:383-393.

94. Hashem MM, Esmael A, Nassar AK, El-Sherif M. The relationship between exacerbated diabetic peripheral neuropathy and metformin treatment in type 2 diabetes mellitus. Sci Rep. 2021;11:1940.

95. Roy RP, Ghosh K, Ghosh M, et al. Study of vitamin B deficiency and peripheral neuropathy in metformin-treated early type 2 diabetes mellitus. Indian J Endocrinol Metab. 2016;20:631-637.

96. Khalaf KM, Khudhair MS, Ashor AW. Vitamin B12 status and peripheral neuropathy in patients with type 2 diabetes mellitus. J Pak Med Assoc. 2019;69(Suppl 3):S40-S44.

97. Russo GT, Giandalia A, Romeo EL, et al. Diabetic neuropathy and metformin treatment in type 2 diabetes mellitus. Nutrients. 2016;8:395-408.

98. Bartley EJ, Fillingim RB. Sex differences in pain: a brief review of clinical and experimental findings. Br J Anaesth. 2013;111:52-58.

99. Assunção A, Campos D, Marques R, et al. The impact of demographic and clinical characteristics on diabetic painful neuropathy. Rom J Intern Med. 2020;58:13-19.

100. Shillo P, Sloan G, Greig M, et al. Painful and painless diabetic neuropathies: what is the difference? Curr Diab Rep. 2019;19:32.

101. Abraham A, Barnett C, Katzberg HD, Lovblom LE, Perkins BA, Bril V. Sex differences in neuropathic pain intensity in diabetes. J Neurol Sci. 2018;388:103-106.

102. Inyang KE, Szabo-Pardi T, Wentworth E, et al. The antidiabetic drug metformin prevents and reverses neuropathic pain and spinal cord microglial activation in male but not female mice. Pharmaco Res. 2019;139:1-16.

103. ‘Kimura N, Masuda S, Tanihara Y, et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005;20:379-386.

104. Groves CE, Suhre WB, Cherrington NJ, Wright SH. Sex differences in the miRNA, protein, and functional expression of organic anion transporter (Oat) 1, Oat3, and organic cation transporter (Oct) 2 in rabbit renal proximal tubules. J Pharmacol Exp Ther. 2006;316:743-752.

105. Asaka J-i, Terada T, Okuda M, Katsura T, Inui K-i. Androgen receptor is responsible for rat organic cation transporter 2 gene regulation but not for rOCT1 and rOCT3. Pharm Res. 2006;23:697-704.

106. Carvalho-E-Silva AP, Ferreira ML, Ferreira PH, Harmer AR. Does type 2 diabetes increase the risk of musculoskeletal pain? Cross-sectional and longitudinal analyses of UK biobank data. Semin Arthritis Rheum. 2020;50:728-734.

107. Simba RD, Nicklett EJ, Ferrucci L. Does accumulation of advanced glycation end products contribute to the aging phenotype? J Gerontol A Biol Sci Med Sci. 2010;65:963-975.

108. Saha AK, Jia S, Wang P. Is metformin a possible treatment for diabetic neuropathy? Journal of Diabetes. 2022;14(10):658-669. doi: 10.1111/1753-0407.13310.

How to cite this article: Wei J, Wei Y, Huang M, Wang P, Jia S. Is metformin a possible treatment for diabetic neuropathy? Journal of Diabetes. 2022;14(10):658-669. doi:10.1111/1753-0407.13310.